Home Cell Cycle CDK inhibitor Roscovitine (Seliciclib)

research use only

Roscovitine (Seliciclib) CDK inhibitor

Cat.No.S1153

Roscovitine is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
Roscovitine (Seliciclib) CDK inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 354.45

Jump to

Quality Control

Batch: Purity: 99.85%
99.85

Cell Culture, Treatment & Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LB771-HNC Growth Inhibition Assay IC50=48.9212 μM SANGER
LB2241-RCC Growth Inhibition Assay IC50=48.6202 μM SANGER
DU-4475 Growth Inhibition Assay IC50=48.4937 μM SANGER
LB2518-MEL Growth Inhibition Assay IC50=47.0448 μM SANGER
NCI-H209 Growth Inhibition Assay IC50=46.0115 μM SANGER
CGTH-W-1 Growth Inhibition Assay IC50=44.9697 μM SANGER
MS-1 Growth Inhibition Assay IC50=42.893 μM SANGER
GI-ME-N Growth Inhibition Assay IC50=42.6671 μM SANGER
DG-75 Growth Inhibition Assay IC50=42.6546 μM SANGER
MLMA Growth Inhibition Assay IC50=42.2787 μM SANGER
HT Growth Inhibition Assay IC50=42.0028 μM SANGER
LC-1F Growth Inhibition Assay IC50=41.5705 μM SANGER
NCI-H1882 Growth Inhibition Assay IC50=40.5998 μM SANGER
NTERA-S-cl-D1 Growth Inhibition Assay IC50=39.5842 μM SANGER
NCI-H345 Growth Inhibition Assay IC50=38.9106 μM SANGER
MONO-MAC-6 Growth Inhibition Assay IC50=38.2477 μM SANGER
RS4-11 Growth Inhibition Assay IC50=37.7069 μM SANGER
ML-2 Growth Inhibition Assay IC50=37.6712 μM SANGER
OPM-2 Growth Inhibition Assay IC50=37.2949 μM SANGER
LU-139 Growth Inhibition Assay IC50=37.1856 μM SANGER
COLO-684 Growth Inhibition Assay IC50=37.012 μM SANGER
MOLT-4 Growth Inhibition Assay IC50=36.3276 μM SANGER
TE-6 Growth Inhibition Assay IC50=36.3246 μM SANGER
TE-441-T Growth Inhibition Assay IC50=36.1148 μM SANGER
IMR-5 Growth Inhibition Assay IC50=35.3139 μM SANGER
K5 Growth Inhibition Assay IC50=35.0861 μM SANGER
TE-10 Growth Inhibition Assay IC50=34.9422 μM SANGER
NCI-H2141 Growth Inhibition Assay IC50=34.6533 μM SANGER
KGN Growth Inhibition Assay IC50=34.2524 μM SANGER
LP-1 Growth Inhibition Assay IC50=33.8908 μM SANGER
NCI-H64 Growth Inhibition Assay IC50=33.8597 μM SANGER
RKO Growth Inhibition Assay IC50=33.5969 μM SANGER
NCI-H526 Growth Inhibition Assay IC50=33.4936 μM SANGER
GOTO Growth Inhibition Assay IC50=32.9129 μM SANGER
Calu-6 Growth Inhibition Assay IC50=32.4745 μM SANGER
LOUCY Growth Inhibition Assay IC50=32.1253 μM SANGER
SK-N-FI Growth Inhibition Assay IC50=31.7535 μM SANGER
SIG-M5 Growth Inhibition Assay IC50=31.6833 μM SANGER
NKM-1 Growth Inhibition Assay IC50=31.1397 μM SANGER
NCI-SNU-1 Growth Inhibition Assay IC50=31.1059 μM SANGER
NCI-H82 Growth Inhibition Assay IC50=31.0135 μM SANGER
NCI-H510A Growth Inhibition Assay IC50=30.0329 μM SANGER
ES3 Growth Inhibition Assay IC50=29.9582 μM SANGER
BB30-HNC Growth Inhibition Assay IC50=29.9483 μM SANGER
KM12 Growth Inhibition Assay IC50=29.6239 μM SANGER
GI-1 Growth Inhibition Assay IC50=29.0113 μM SANGER
NOS-1 Growth Inhibition Assay IC50=28.9733 μM SANGER
TE-8 Growth Inhibition Assay IC50=28.908 μM SANGER
TE-9 Growth Inhibition Assay IC50=28.7969 μM SANGER
HL-60 Growth Inhibition Assay IC50=27.9869 μM SANGER
QIMR-WIL Growth Inhibition Assay IC50=27.9144 μM SANGER
KARPAS-299 Growth Inhibition Assay IC50=26.8646 μM SANGER
KURAMOCHI Growth Inhibition Assay IC50=26.8082 μM SANGER
BL-41 Growth Inhibition Assay IC50=25.9597 μM SANGER
NCI-H2126 Growth Inhibition Assay IC50=25.6529 μM SANGER
HOP-62 Growth Inhibition Assay IC50=25.4425 μM SANGER
IST-SL2 Growth Inhibition Assay IC50=24.5343 μM SANGER
HH Growth Inhibition Assay IC50=24.3819 μM SANGER
LS-513 Growth Inhibition Assay IC50=23.5179 μM SANGER
EB-3 Growth Inhibition Assay IC50=23.1831 μM SANGER
ACN Growth Inhibition Assay IC50=21.3389 μM SANGER
NOMO-1 Growth Inhibition Assay IC50=21.2008 μM SANGER
ES8 Growth Inhibition Assay IC50=21.06 μM SANGER
CESS Growth Inhibition Assay IC50=20.8549 μM SANGER
BL-70 Growth Inhibition Assay IC50=20.3274 μM SANGER
MHH-PREB-1 Growth Inhibition Assay IC50=20.0356 μM SANGER
BC-1 Growth Inhibition Assay IC50=19.1198 μM SANGER
LC4-1 Growth Inhibition Assay IC50=18.8734 μM SANGER
COLO-320-HSR Growth Inhibition Assay IC50=18.7688 μM SANGER
A101D Growth Inhibition Assay IC50=18.3208 μM SANGER
BC-3 Growth Inhibition Assay IC50=18.0305 μM SANGER
TGW Growth Inhibition Assay IC50=17.8124 μM SANGER
JAR Growth Inhibition Assay IC50=17.0152 μM SANGER
HD-MY-Z Growth Inhibition Assay IC50=16.8246 μM SANGER
NCI-H1304 Growth Inhibition Assay IC50=16.3601 μM SANGER
OS-RC-2 Growth Inhibition Assay IC50=15.8382 μM SANGER
OCI-AML2 Growth Inhibition Assay IC50=15.6482 μM SANGER
HCC1599 Growth Inhibition Assay IC50=14.5975 μM SANGER
SCC-3 Growth Inhibition Assay IC50=14.2956 μM SANGER
RPMI-6666 Growth Inhibition Assay IC50=13.9121 μM SANGER
MEG-01 Growth Inhibition Assay IC50=13.8379 μM SANGER
Raji Growth Inhibition Assay IC50=13.7894 μM SANGER
RPMI-8402 Growth Inhibition Assay IC50=13.6262 μM SANGER
GCIY Growth Inhibition Assay IC50=12.8613 μM SANGER
697 Growth Inhibition Assay IC50=12.6007 μM SANGER
D-247MG Growth Inhibition Assay IC50=12.3516 μM SANGER
NB1 Growth Inhibition Assay IC50=12.3308 μM SANGER
COR-L279 Growth Inhibition Assay IC50=12.2907 μM SANGER
LB831-BLC Growth Inhibition Assay IC50=11.5624 μM SANGER
ST486 Growth Inhibition Assay IC50=10.351 μM SANGER
SK-UT-1 Growth Inhibition Assay IC50=10.35 μM SANGER
BB65-RCC Growth Inhibition Assay IC50=9.97495 μM SANGER
KARPAS-422 Growth Inhibition Assay IC50=9.96336 μM SANGER
Becker Growth Inhibition Assay IC50=9.46082 μM SANGER
KS-1 Growth Inhibition Assay IC50=9.45785 μM SANGER
JiyoyeP-2003 Growth Inhibition Assay IC50=8.50264 μM SANGER
NCCIT Growth Inhibition Assay IC50=7.55482 μM SANGER
MRK-nu-1 Growth Inhibition Assay IC50=7.12969 μM SANGER
A3-KAW Growth Inhibition Assay IC50=5.76116 μM SANGER
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 15958589
LP-1 Apoptosis assay 30 uM 3 hrs Induction of apoptosis in human LP-1 cells at 30 uM after 3 hrs using TUNEL staining by flow cytometry 15958589
LP-1 Cytotoxicity assay 20 to 30 uM 24 hrs Cytotoxicity against human LP-1 cells assessed as reduction of cell viability at 20 to 30 uM treated for 24 hrs followed by washout measured after total 72 hrs growth period alamar blue assay relative to control 15958589
LP-1 Apoptosis assay 30 uM 1.5 hrs Induction of apoptosis in human LP-1 cells assessed as reduction of RNA polymerase 2 phosphoserine 2 level at 30 uM after 1.5 hrs by immunoblotting 15958589
LP-1 Apoptosis assay 30 uM 3 hrs Induction of apoptosis in human LP-1 cells assessed as reduction of Mcl-1 protein level at 30 uM after 3 hrs by immunoblotting 15958589
LP-1 Apoptosis assay 30 uM 3 to 5 hrs Induction of apoptosis in human LP-1 cells assessed as increase in level of cleaved PARP at 30 uM after 3 to 5 hrs by immunoblotting 15958589
NCI-H929 Apoptosis assay 30 uM 5 hrs Induction of apoptosis in human NCI-H929 cells assessed as increase in level of cleaved PARP at 30 uM after 5 hrs by immunoblotting 15958589
NCI-H929 Apoptosis assay 30 uM 1.5 hrs Induction of apoptosis in human NCI-H929 cells assessed as fast slow migrating hyperphosphorylated RNA polymerase 2O form at 30 uM after 1.5 hrs by immunoblotting 15958589
RPM18226 Apoptosis assay 30 uM 1.5 hrs Induction of apoptosis in human RPM18226 cells assessed as reduction of RNA polymerase 2 phosphoserine 2 level at 30 uM after 1.5 hrs by immunoblotting 15958589
RPM18226 Apoptosis assay 30 uM 3 hrs Induction of apoptosis in human RPM18226 cells assessed as reduction of Mcl-1 protein level at 30 uM after 3 hrs by immunoblotting 15958589
RPM18226 Apoptosis assay 30 uM 3 to 5 hrs Induction of apoptosis in human RPM18226 cells assessed as increase in level of cleaved PARP at 30 uM after 3 to 5 hrs by immunoblotting 15958589
NCI-H929 Apoptosis assay 30 uM 3 hrs Induction of apoptosis in human NCI-H929 cells assessed as changes in XIAP protein level at 30 uM after 3 hrs by immunoblotting 15958589
NCI-H929 Apoptosis assay 30 uM 3 hrs Induction of apoptosis in human NCI-H929 cells assessed as changes in survivin protein level at 30 uM after 3 hrs by immunoblotting 15958589
RPM18226 Apoptosis assay 30 uM 3 hrs Induction of apoptosis in human RPM18226 cells at 30 uM after 3 hrs using TUNEL staining by flow cytometry 15958589
NCI-H929 Apoptosis assay 30 uM 1.5 hrs Induction of apoptosis in human NCI-H929 cells assessed as reduction of RNA polymerase 2 phosphoserine 2 level at 30 uM after 1.5 hrs by immunoblotting 15958589
NCI-H929 Apoptosis assay 30 uM 1.5 hrs Induction of apoptosis in human NCI-H929 cells assessed as dephosphorylation of pRb at S249/T252 at 30 uM after 1.5 hrs by immunoblotting 15958589
NCI-H929 Cytotoxicity assay 20 to 30 uM 16 hrs Cytotoxicity against human NCI-H929 cells assessed as reduction of cell viability at 20 to 30 uM treated for 16 hrs followed by washout measured after total 72 hrs growth period alamar blue assay relative to control 15958589
NCI-H929 Apoptosis assay 30 uM 3 hrs Induction of apoptosis in human NCI-H929 cells assessed as reduction of Mcl-1 protein level at 30 uM after 3 hrs by immunoblotting 15958589
NCI-H929 Apoptosis assay 30 uM 3 hrs Induction of apoptosis in human NCI-H929 cells assessed as changes in Bcl-2 protein level at 30 uM after 3 hrs by immunoblotting 15958589
NCI-H929 Apoptosis assay 30 uM 3 hrs Induction of apoptosis in human NCI-H929 cells at 30 uM after 3 hrs using TUNEL staining by flow cytometry 15958589
NCI-H929 Apoptosis assay 30 uM 1.5 hrs Induction of apoptosis in human NCI-H929 cells assessed as reduction of RNA polymerase 2 phosphoserine 5 level at 30 uM after 1.5 hrs by immunoblotting 15958589
NCI-H929 Apoptosis assay 30 uM 1.5 hrs Induction of apoptosis in human NCI-H929 cells assessed as reduction of Hdm2 level at 30 uM after 1.5 hrs by immunoblotting 15958589
NCI-H929 Apoptosis assay 30 uM 1.5 hrs Induction of apoptosis in human NCI-H929 cells assessed as increase of p53 accumulation at 30 uM after 1.5 hrs by immunoblotting 15958589
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 21080703
HCT116 Function assay 30 to 40 umol/L 24 hrs Inhibition of cyclin A in human HCT116 cells assessed as decrease in protein level at 30 to 40 umol/L after 24 hrs by immunoblotting analysis 21080703
HCT116 Function assay 30 to 40 umol/L 24 hrs Inhibition of cyclin B in human HCT116 cells assessed as decrease in protein level at 30 to 40 umol/L after 24 hrs by immunoblotting analysis 21080703
HCT116 Function assay 30 to 40 umol/L 24 hrs Inhibition of cyclin D1 in human HCT116 cells assessed as decrease in protein level at 30 to 40 umol/L after 24 hrs by immunoblotting analysis 21080703
HCT116 Function assay 30 to 40 umol/L 24 hrs Inhibition of CDK2 in human HCT116 cells assessed as decrease in protein level at 30 to 40 umol/L after 24 hrs by immunoblotting analysis 21080703
HT-29 Function assay 2.5 to 40 uM 24 hrs Inhibition of retinoblastoma protein in human HT-29 cells assessed as reduction of cyclin A level at 2.5 to 40 uM after 24 hrs by immunoblotting 21417417
MCF7 Cell cycle assay 24 hrs Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide and BrdU staining by flow cytometry 21417417
RPMI8226 Cell cycle assay 24 hrs Cell cycle arrest in human RPMI8226 cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide and BrdU staining by flow cytometry 21417417
MCF7 Cell cycle assay 24 hrs Cell cycle arrest in human MCF7 cells assessed as decrease in S phase cell population after 24 hrs using propidium iodide and BrdU staining by flow cytometry 21417417
MCF7 Cell cycle assay 24 hrs Cell cycle arrest in human MCF7 cells assessed as accumulation at sub-G1 phase after 24 hrs using propidium iodide and BrdU staining by flow cytometry 21417417
RPMI8226 Cell cycle assay 24 hrs Cell cycle arrest in human RPMI8226 cells assessed as accumulation at sub-G1 phase after 24 hrs using propidium iodide and BrdU staining by flow cytometry 21417417
MCF7 Cell cycle assay 80 uM 24 hrs Cell cycle arrest in human MCF7 cells assessed as reduction of actively replicating DNA level at 80 uM after 24 hrs using propidium iodide and BrdU staining by flow cytometry 21417417
MCF7 Function assay 20 uM 24 hrs Induction of p53-dependent transcriptional activity in human MCF7 cells assessed as increase of p21 WAF1 level at 20 uM after 24 hrs by immunofluorescence assay 21417417
RPMI8226 Cell cycle assay 24 hrs Cell cycle arrest in human RPMI8226 cells assessed as decrease in S phase cell population after 24 hrs using propidium iodide and BrdU staining by flow cytometry 21417417
RPMI8226 Cell cycle assay 80 uM 24 hrs Cell cycle arrest in human RPMI8226 cells assessed as reduction of actively replicating DNA level at 80 uM after 24 hrs using propidium iodide and BrdU staining by flow cytometry 21417417
A549 Apoptosis assay 2 uM 48 hrs Induction of apoptosis in human A549 cells assessed as DNA fragmentation at 2 uM after 48 hrs by agarose gel electrophoresis 23623491
Sf9 Function assay 10 mins Inhibition of His-6-tagged recombinant human CDK2/cyclinE expressed in baculovirus-infected sf9 cells using histone H1 as substrate after 10 mins by liquid scintillation counting in presence of [gamma-32P]ATP, IC50 = 0.1 μM. 24417566
BJ Function assay 10 uM 10 days Suppression of senescence in human BJ cells assessed as increase in cell number at 10 uM after 10 days by senescence reversal assay 24681986
BJ Function assay 10 uM 10 days Inhibition of ataxia telangiectasia-mutated in human BJ cells assessed as increase in cell number at 10 uM after 10 days by senescence reversal assay 24681986
MCF7 Function assay 10 uM 10 mins Sensitization of infrared-induced DNA damage in human MCF7 cells assessed as reduction in colony formation at 10 uM pretreated for 10 mins followed by irradiation for 4 hrs measured after 10 days by crystal violet staining analysis 26851505
Caco2 Cell cycle assay Cell cycle arrest in human Caco2 cells assessed as accumulation at G1/S phase by Hoechst staining based fluorescence assay 28214231
HaCaT Cell cycle assay Cell cycle arrest in human HaCaT cells assessed as accumulation at G1/S phase by Hoechst staining based fluorescence assay 28214231
HuH7 Cell cycle assay Cell cycle arrest in human HuH7 cells assessed as accumulation at G1/S phase by Hoechst staining based fluorescence assay 28214231
PC3 Cell cycle assay Cell cycle arrest in human PC3 cells assessed as accumulation at G2/M phase by Hoechst staining based fluorescence assay 28214231
MDA-MB-231 Cell cycle assay Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G1/S phase by Hoechst staining based fluorescence assay 28214231
HCT116 Cell cycle assay Cell cycle arrest in human HCT116 cells assessed as accumulation at G1/S phase by Hoechst staining based fluorescence assay 28214231
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 28557430
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 30199702
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 71 mg/mL (200.31 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 71 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 354.45 Formula

C19H26N6O

 Storage (From the date of receipt)
CAS No. 186692-46-6 Download SDF Storage of Stock Solutions

Synonyms CYC202, Seliciclib, R-roscovitine Smiles CCC(CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=CC=C3

Mechanism of Action

Targets/IC50/Ki
CDK5/p35
(Cell-free assay)
0.16 μM
Cdc2/CyclinB
(Cell-free assay)
0.65 μM
CDK2/CyclinA
(Cell-free assay)
0.7 μM
CDK2/CyclinE
(Cell-free assay)
0.7 μM
ERK2
(Cell-free assay)
14 μM
In vitro

Roscovitine displays high efficiency and high selectivity towards some cyclin-dependent kinases with IC50 of 0.65, 0.7, 0.7 and 0.16 μM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E and cdk5/p53, respectively. This compound reversibly inhibits the prophaselmetaphase transition in the micromolar range of starfish oocytes and sea urchin embryos, inhibits in vitro M-phase-promoting factor activity and in vitro DNA synthesis in Xenopus egg extracts, and suppresses the proliferation of mammalian cell lines with an average IC50 of 16 μM. In mesangial cells, it results in a dose-dependent reduction of CDK2 activity that at concentrations of 7.5, 12.5 and 25 mM, this chemical causes a 25, 50% and 100% decrease in CDK2 activity, respectively. A recent study shows that this compound inhibits cdk5 kinase activity, cell proliferation, multicellular development, and cdk5 nuclear translocation in Dictyostelium discoideum, without affecting the expression of cdk5 protein during axenic growth.

Kinase Assay
Enzymes
[API调用失败: invalid chat.event: ping, {'event': 'ping', 'data': '{"timestamp_ms":"1763706911366"}'}]
In vivo

Roscovitine, at a dose of 50 mg/kg, significantly inhibits growth of The Ewing's sarcoma family of tumors (ESFT) xenografts. This compound enhances the antitumor effect of doxorubicin without increased toxicity with a mechanism that involves cell cycle arrest rather than apoptosis in nude mice bearing established MCF7 xenografts.

References
  • [4] https://pubmed.ncbi.nlm.nih.gov/16230394/
  • [5] https://pubmed.ncbi.nlm.nih.gov/19003963/

Applications

Methods Biomarkers Images PMID
Western blot pT231-tau / pS202-tau / tau p-Rb / p-CDK2 / CDK2 / Cyclin D1 / Cyclin A2 / ERα / ERβ/ AIB1 / PELP1
S1153-WB2
30915013
Immunofluorescence CDK1 / Smek2 / FUBP1 / Cdc20 E2F1 / FASN / Bmi1 / Cyclin D2 / CDK2 / CDK4
S1153-IF2
24534090
Growth inhibition assay Cell viability
S1153-viability1
29996940

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02649751 Terminated
Cystic Fibrosis
University Hospital Brest|ManRos Therapeutics|Cyclacel Pharmaceuticals Inc.
 February 22 2016 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How can I reconstitute it for in vivo studies?

Answer:
It in 1% DMSO+10% Tween 80+20% N-N-dimethylacetamide+PEG 400 is a clear solution which is okay for injection. And this compound in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension, which is fine for oral gavage.

Signaling Pathway Map